Navigation Links
Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial
Date:4/18/2011

BEDFORD, Ohio,  April 18, 2011 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio.  Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline. Topotecan Hydrochloride for Injection is indicated for the treatment of metastic carcinoma of the ovary after failure of initial or subsequent chemotherapy.  Additionally, this product is used to treat small cell lung cancer. It is used in combination with cisplatin to treat cancer of the cervix, which cannot be treated with surgery or radiation therapy.

(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO)

Bedford Laboratories Topotecan Hydrochloride for Injection, 4 mg (base)/vial is sold individually and is latex free, UPC bar coded and preservative free.  This launch is an example of how Bedford Laboratories goes Beyond, Above-and-Beyond to provide our customers with pharmaceutical products that improve people's health and quality of life.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories produces an extensive selection of critical-care and medically necessary medications, including oncology products, cardiac agents, anesthesia products and other therapeutic class injectables. We recognize the importance of making sure that physicians and patients have access to the products they need when they need them. At Bedford Laboratories, quality is paramount. We take the utmost care in producing a high-quality reliable product supply to the market.  

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people.  For more information and current career opportunities, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  Please visit http://us.boehringer-ingelheim.com.

Hycamtin®   is a registered trademark of GlaxoSmithKline


'/>"/>
SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bedford Laboratories™ to Begin Shipping Dactinomycin for Injection USP 500 mcg (0.5 mg)
2. Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
3. Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
4. ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter
5. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
6. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
7. Texas Childrens Is First Pediatric Hospital To Begin Certification Process for SynCardias Total Artificial Heart
8. Bacterin International Announces Major Orthopedic Hospital Group to Begin Use of OsteoSponge®SC
9. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
10. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
11. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Marziani has joined VMS BioMarketing as senior vice president of sales, announced Andrea ... Marziani will lead the company,s business development and sales team, exploring new opportunities for ... - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... 24, 2016 Open Access Journal ... Neurophysiology  Elsevier , a world-leading provider ... today announced the launch of Clinical Neurophysiology ... that focuses on clinical practice issues in clinical neurophysiology. ... series, normal values and didactic reviews. It is an ...
(Date:5/23/2016)... May 23, 2016 Global Paclitaxel ... pages, profiles 12 companies and the Paclitaxel analysis in ... on the industry and its players. This ... in nature, details the current state of the industry ... definitions, classifications, applications and industry chain structure. The Paclitaxel ...
Breaking Medicine Technology:
(Date:5/25/2016)... San Diego, CA (PRWEB) , ... May 25, 2016 , ... There was a time ... more women are going with the flow and turning to menstrual cups, like Lunette ... a party, Lunette is introducing their new anthem in this catchy video ! ...
(Date:5/25/2016)... Indiana (PRWEB) , ... May 25, 2016 , ... ... Network Service Provider, announces that Lake City Bank has selected IFN as a ... manage carrier access, resulting in increased efficiencies and reduced costs. , ...
(Date:5/25/2016)... MA (PRWEB) , ... May 25, 2016 , ... ... Research Institute (WCRI) compare outcomes of injured workers across 15 states. The ... to work, earnings recovery, access to medical care, and satisfaction with medical care. ...
(Date:5/25/2016)... ... May 25, 2016 , ... CloudLIMS, joins an elite number of ... Tech Solution Providers list of 2016 by CIOReview. , In a deliberate session with ... Tech Solution Providers 2016 has been concluded with. The positioning is based on evaluation ...
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular ... through Molecular Imaging.” The focus of ADDMI-IG will be geared towards how using ... pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive discussions about ...
Breaking Medicine News(10 mins):